Group 1 - The Hang Seng Index fell by 0.1%, down 26 points, closing at 26,559 points, while the Hang Seng Tech Index decreased by 0.4% [1] - Baidu Group-SW (09888) rose by 4%, leading blue-chip stocks, as it officially launched the Wenxin large model version 5.0 [2] - Tianzu Zhixin (09903) surged over 14%, reaching a new high since its listing, and is set to release a roadmap for its next three generations of GPGPU products on January 26 [2] Group 2 - Minth Group (00425) increased by over 10%, benefiting from the growth of electric vehicles in Europe and actively entering the humanoid robot and liquid cooling sectors [3] - Junda Co., Ltd. (002865) (02865) rose over 14%, planning to raise funds through a placement at a discount of approximately 1.08% for the development of space photovoltaic battery products [3] - In A-shares, stocks hit the daily limit [3] Group 3 - Kintor Pharmaceutical (03696) increased by over 5%, achieving a new peak as its AI-enabled drug development capabilities for tumors received further recognition [3] - Kintao Group saw early gains, with Kintao Laminated Board (01888) rising over 2%, as Goldman Sachs remains optimistic about China's PCB and CCL industries [4] Group 4 - Pacific Basin Shipping (02343) rose over 7%, reaching a new high as the BDI index climbed to a two-week high [5] - China Shipbuilding Industry Corporation (600685) (00317) increased by over 3%, with its 2025 performance forecast meeting market expectations, and it is expected to benefit from the integration of shipbuilding assets [5] Group 5 - CNOOC Services (601808) (02883) rose over 4%, converting $746 million in debt to equity to enhance its oil and gas business in Norway [6] Group 6 - Kingsray Biotech (01548) fell over 6%, as its joint venture Legend Biotech saw its stock price drop by more than 11% overnight [7] - Nanshan Aluminum (600219) International (02610) dropped over 8%, conducting a placement at a 6.4% discount, raising a net of HKD 1.99 billion [8] - Market risk aversion decreased, leading to a pullback in precious metal prices, with gold stocks experiencing significant declines, including Chifeng Jilong Gold Mining (600988) (06693) down 3.73% and Lingbao Gold (03330) down 3.4% [8] Group 7 - New stock Longqi Technology (603341) (09611) debuted, closing at HKD 32.2, up 4.84% on its first trading day [9]

英矽智能（03696）盘中涨超7%，高见61.30港元，再创新高。截至发稿，股价上涨5.44%，报60.10港 元，成交额6132.68万港元。 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 英矽智能（03696）盘中涨超7%，高见61.30港元，再创新高。截至发稿，股价上涨5.44%，报60.10港 元，成交额6132.68万港元。 英矽智能近日与施维雅达成多年期研发合作，将利用AI平台Pharma.AI开发抗肿瘤药物。中邮证券发布 研报称，英矽智能在AI驱动的肿瘤药物研发方面经验丰富，已建立覆盖多种癌症适应症的管线。其中 泛TEAD抑制剂ISM6331和MAT2A抑制剂ISM3412已启动全球多中心I期临床试验，另有四个肿瘤项目已 对外授权。 国投证券国际表示，英矽智能基石投资者阵容豪华，在AI药物发现领域处于行业领先地位。公司自主 开发的生成式人工智能平台Pharma.AI，已孵化出逾20项临床或IND申报阶段的资产，其中三项资产已 授权给国际制药企业，合约总价值最高达21亿美元，以及一项处于自主开发阶段的II期资产。 ...

Core Viewpoint - The stock of Insilico Medicine (03696) has risen over 7%, reaching a new high of 61.3 HKD, driven by a long-term R&D collaboration with Sivea to develop anti-tumor drugs using the AI platform Pharma.AI [1] Group 1: Company Developments - Insilico Medicine has extensive experience in AI-driven tumor drug development and has established a pipeline covering various cancer indications [1] - The company has initiated global multi-center Phase I clinical trials for two drugs: the pan-TEAD inhibitor ISM6331 and the MAT2A inhibitor ISM3412, with four additional tumor projects licensed out [1] - Insilico's proprietary generative AI platform, Pharma.AI, has incubated over 20 assets in clinical or IND application stages, with three assets licensed to international pharmaceutical companies, totaling a contract value of up to 2.1 billion USD [1] Group 2: Market Performance - As of the latest report, Insilico Medicine's stock is trading at 58.15 HKD with a trading volume of 48.29 million HKD [1] - The company has a strong base of cornerstone investors and is positioned as a leader in the AI drug discovery field [1]

Core Viewpoint - Incyte Corporation (03696) has seen its stock price rise over 7%, reaching a new high of 61.3 HKD, driven by a long-term R&D collaboration with Sivea to develop anti-tumor drugs using the AI platform Pharma.AI [1] Group 1: Company Developments - Incyte has extensive experience in AI-driven tumor drug development and has established a pipeline covering various cancer indications [1] - The company has initiated global multi-center Phase I clinical trials for two drugs: TEAD inhibitor ISM6331 and MAT2A inhibitor ISM3412, with four additional tumor projects already licensed out [1] Group 2: Financial and Market Position - According to Zhongyou Securities, Incyte's strong investor base positions it as a leader in the AI drug discovery field [1] - The Pharma.AI platform has incubated over 20 assets in clinical or IND application stages, with three assets licensed to international pharmaceutical companies, totaling contract values up to 2.1 billion USD, alongside one asset in Phase II development [1]

Core Viewpoint - Baiaosaitu-B (02315) has seen a significant increase in stock price, rising nearly 7% and currently trading at 39.72 HKD, with a transaction volume of 28.32 million HKD. The company has completed the localization of its AI-driven antibody drug development platform, enhancing synergy with its core business, the "Thousand Mice and Ten Thousand Antibodies" initiative [1]. Group 1 - The company has successfully localized its AI-driven antibody drug development platform [1]. - The integration of the AI system with the "Thousand Mice and Ten Thousand Antibodies" plan is ongoing, which is expected to provide more efficient research tools and a richer antibody molecule library for global pharmaceutical companies [1]. - This development aims to improve the efficiency of preclinical PCC molecule research for pharmaceutical partners, marking a new phase in the antibody discovery business [1].

Core Viewpoint - Dongyangguang Pharmaceutical is advancing its AI strategy by launching an AI-driven research and development platform focused on the PROTAC mechanism, aiming to provide a comprehensive data foundation for rational design and clinical translation of PROTAC lead compounds [1][2]. Group 1: AI Strategy and Platform Development - The company is building a high-quality, structured PROTAC-specific database (HEC PROTAC DB) that integrates molecular structures, degradation activity, physicochemical properties, and pharmacokinetic parameters from clinical pipelines, patents, and literature [2]. - The database currently includes over 30,000 PROTAC molecules, more than 500 POI ligands, over 1,000 types of linkers, 200 E3 ligands, and more than 150 targets, significantly surpassing existing public databases in data scale and structural granularity [2]. - An AI molecular generation and screening platform has been developed based on this database, creating a "data-generation-computational validation-experimental feedback" closed loop to accelerate the rational design and clinical translation of PROTAC lead compounds [2]. Group 2: Collaboration and Drug Development - The company is enhancing its AI drug development strategy through collaborations with industry leaders such as Beijing Deep Technology Co., Ltd. and Huawei Cloud Computing Technology Co., Ltd., establishing six proprietary models covering the entire drug discovery process [3]. - The first AI-driven small molecule drug, HEC169584, targeting metabolic-associated fatty liver disease (MASH), has entered clinical phase I, showing high in vitro activity against THR-β cells and strong liver targeting, with reduced impact on the thyroid axis and heart [3].

Core Insights - The company is advancing its AI strategy by launching an AI-driven research platform focused on PROTAC mechanisms, which enhances the rational design of lead compounds and clinical translation through a comprehensive data foundation [1][2] Group 1: AI Strategy and Platform Development - The AI platform aims to create a high-quality, structured PROTAC-specific database (HEC-PROTACDB) that integrates molecular structures, degradation activities, physicochemical properties, and pharmacokinetic parameters from clinical pipelines, patents, and literature [2] - The database currently includes over 30,000 PROTAC molecules, more than 500 POI ligands, over 1,000 types of linkers, 200 E3 ligands, and more than 150 targets, significantly surpassing existing public databases in data scale and structural granularity [2] Group 2: Drug Development and Collaborations - The company is enhancing its AI drug development strategy through collaborations with industry leaders such as Beijing DeepTech and Huawei Cloud, establishing six proprietary models that cover the entire drug discovery process from molecular design to prescription design [3] - The first AI-driven small molecule drug, HEC169584, targeting metabolic-associated fatty liver disease (MASH), has entered clinical phase I, showing high in vitro activity against THR-β cells and strong liver targeting, with reduced impact on the thyroid axis and heart [3]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 – 1 – SUNSHINE LAKE PHARMA CO., LTD. 廣 東 東 陽 光 藥 業 股 份 有 限 公 司 （在中華人民共和國註冊成立之股份有限公司） （股份代號：6887） 自願性公告 推出全球領先的PROTAC機制AI智能研發平台 本 公 告 由 廣 東 東 陽 光 藥 業 股 份 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團」）自願刊發。 本集團持續深化AI戰略佈局，推出面向PROTAC機制的AI智能研發平台，實現從 數據底座到「乾濕閉環」，數據規模與結構粒度均顯著領先於現有公開數據庫，為 AI 驅 動的 PROTAC 理 性設 計 提供 了 全面 、 系 統的 數 據基 礎 ，加 速 PROTAC 先導 化 合物的理性設計與臨床轉化。 研發背景：破解「不可成藥」困局，PR ...

2026.01. 14 本文字数：1240，阅读时长大约2分钟 作者 | 一财阿驴 11:31 A股午盘丨沪指剑指4200点 截至午盘，沪指涨1.2%，剑指4200点；深成指涨1.98%，创业板指涨2.24%，科创综指涨3.55%。 | 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | 000001 | 上证指数 | 21 | 4188.24 | 49.48 | 1.20% | | 399001 | 深证成指 | m. | 14449.57 | 280.18 | 1.98% | | 399006 | 创业板指 | my | 3396.35 | 74.47 | 2.24% | | 000680 | 科创综指 | m | 1870.20 | 64.18 | 3.55% | 盘面上，AI应用、金融科技、电商、算力硬件、半导体、核聚变、光伏概念股活跃。 市场逾4700股上涨。沪深两市半日成交额2.22万亿，较上个交易日缩量2155亿。 10:59 阿里云概念盘中持续走高，杭钢股份、数据港涨停，荣信文化涨超10%，浙数文化、润 ...

Core Viewpoint - The stock of Baiaosaitu-B (02315) has increased over 12% and approximately 30% in the last three days, indicating strong market interest and positive sentiment towards the company's developments [1] Group 1: Company Developments - Baiaosaitu has completed the localization deployment of its AI-driven antibody drug research platform, which is now fully integrated with its core business, the "Thousand Mice and Ten Thousand Antibodies" program [1] - The company is building an AI intelligence system for antibody drug development, which aims to provide global pharmaceutical companies with more efficient research tools and a richer library of antibody molecules [1] - The ongoing integration of the "Thousand Mice and Ten Thousand Antibodies" program with the AI system is expected to enhance the efficiency of preclinical PCC molecule development for pharmaceutical partners, marking a new phase in antibody discovery business [1] Group 2: Strategic Partnerships - Baiaosaitu has entered into an option and licensing agreement with Yushibo to systematically evaluate the BsADC (bispecific antibody-drug conjugate) project through a structured assessment mechanism [1] - This partnership aims to accelerate the development process of BsAD2C (bispecific antibody dual drug conjugate) [1]